Form 8-K - Current report:
SEC Accession No. 0001193125-24-011355
Filing Date
2024-01-19
Accepted
2024-01-19 17:22:30
Documents
16
Period of Report
2024-01-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d737189d8k.htm   iXBRL 8-K 38376
2 EX-1.1 d737189dex11.htm EX-1.1 245027
3 EX-5.1 d737189dex51.htm EX-5.1 7252
7 GRAPHIC g737189g0119141035793.jpg GRAPHIC 2825
8 GRAPHIC g737189g98c96.jpg GRAPHIC 13752
  Complete submission text file 0001193125-24-011355.txt   512269

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20240117.xsd EX-101.SCH 2889
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20240117_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20240117_pre.xml EX-101.PRE 11287
10 EXTRACTED XBRL INSTANCE DOCUMENT d737189d8k_htm.xml XML 3396
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1215
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 24546495
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)